| Title |
Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease
|
|---|---|
| Published in |
Drugs, September 2012
|
| DOI | 10.2165/11533070-000000000-00000 |
| Pubmed ID | |
| Authors |
Richard Dodel, Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang Oertel |
| Abstract |
Current treatment options for Alzheimer's disease (AD) exert only a short-lived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing beta-amyloid (Abeta) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Abeta) that specifically recognize and block the toxic effects of Abeta. Furthermore, these nAbs-Abeta are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Abeta, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders. |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| France | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 84 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 20% |
| Student > Ph. D. Student | 14 | 16% |
| Student > Bachelor | 12 | 14% |
| Student > Master | 9 | 10% |
| Student > Postgraduate | 6 | 7% |
| Other | 18 | 20% |
| Unknown | 11 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 39% |
| Agricultural and Biological Sciences | 14 | 16% |
| Psychology | 7 | 8% |
| Neuroscience | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 5 | 6% |
| Unknown | 20 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2023.
All research outputs
#5,447,195
of 25,374,917 outputs
Outputs from Drugs
#833
of 3,464 outputs
Outputs of similar age
#39,056
of 189,085 outputs
Outputs of similar age from Drugs
#278
of 1,461 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,464 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,085 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 1,461 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.